Kornimate/medical-research-clean huggingface dataset:
effect of home-fortification with sprinkles in hematologic and nutritional status in preschool children in medellín

Conditions: Malnutrition

Summary: objective: to acquire the local scientific evidence, to evaluate the effects of micronutrient sprinkles™ powder, both the nutritional status and haematological values in the vulnerable preschool population, to corroborate the reported benefits of the experiences in other countries. question: will it improve the nutritional status and hematological levels after the home fortification with sprinkles in children of two child care centres in the city of medellin, in 2013? hypothesis: at the end of intervention, hematologic levels and anthropometric indicators will be better in the intervention group with sprinkles, compared with the placebo group. design: randomized clinical trial, triple-blind and placebo-controlled. participants: two groups of 50 children each, aged between 5 and 59 months, not anemic or with severe malnourished, full-time assistants to two children's centres that have the same alimentation menu. intervention: the daily diet will be supplemented with sprinkles in one of the children's centres and will be compared anthropometric and hematological values before and after with a group receiving the same diet with placebo. outcome measures: nutritional status (anthropometric measures) and haematological values (hemoglobin, ferritin, transferrin and folate).


Eligibility criteria:
inclusion criteria: * assistance to children's centres full day (8 hours). * age 5 to 59 months. exclusion criteria: * anemia (hemoglobin less than 11 g / dl). * current supplementation with a product formulated by a health professional as a part of a nutritional recovery. * denial for informed consent signing by parents or legal guardians. * diagnosis of severe acute malnutrition by anthropometric measurements.

Keywords: trace elements preschool malnutrition fortified food
bci-controlled nmes in subacute stroke

Conditions: Stroke

Summary: stroke patients with severe upper limb movement deficits have limited treatment options and often remain severely handicapped at the chronic stage. recent findings have suggested that poor motor recovery can be due to severe damage of the cortico-spinal tract (cst), the neural fibres connecting the movement regions of the brain to the spinal cord. hence, to improve recovery of upper limb movements it will be crucial to re-establish and strengthen cst projections. recent studies provided evidence that closed-loop brain computer interface-driven electrical stimulation of the paretic muscles can induce clinically important and lasting recovery of upper limb function, even in patients with chronic, severe motor affection. in this treatment approach, movement intentions of the patients are detected with electroencephalography and real-time analyses. this triggers an electrical stimulation of affected upper limb muscles. in this study, the investigators hypothesize that neuromuscular electrical stimulation (nmes) applied contingent to voluntary activation of primary motor cortex, as detected by a brain-computer interface (bci), can help restore cst projections. this might improve recovery of patients with severe upper limb movement deficits. treatment will be started within the first 8 weeks after stroke onset.


Eligibility criteria:
inclusion criteria: * ischemic or hemorrhagic stroke * stroke onset ≤ 8 weeks * severe, unilateral motor upper extremity hemiparesis (≤15 fugl-meyer score) * ability to give informed consent exclusion criteria: * second stroke during rehabilitation * skull breach * cardiac pacemaker * metallic implants in the brain * delirium or disturbed vigilance * inability to follow treatments sessions * severe language comprehension deficits * severe dystonia or spasticity * severe co-morbidity (ex, traumatic, rheumatologic, neurodegenerative diseases) * pregnancy
an observational cross-sectional study evaluating the use of re-sources and the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation with a risk of stroke or systemic embolism on anticoagulant therapy and treated in primary care centers

Conditions: Stroke; Prevention and Control; Atrial Fibrillation

Summary: this is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (nvaf) at risk of stroke or systemic embolism, who at least three months ago changed their anticoagulant therapy, due to any clinical situation, and are currently on treatment with a direct oral anticoagulant (doac)


Eligibility criteria:
inclusion criteria: * patients ≥18 years of age diagnosed with non-valvular atrial fibrillation with a risk of stroke or systemic embolism treated in primary care centres. * patients on regular treatment with anticoagulants who have changed their therapeutic regimen due to any clinical situation and have been on treatment with a direct oral anticoagulant for at least three months before being recruited (date of signing the in-formed consent). * patients whose first direct oral anticoagulant prescription is written by the specialist (cardiologist, haematologist, internist, etc.) and who are followed in primary care. * patients who have given their informed consent in writing. exclusion criteria: * patients who changed their anticoagulant therapy within a period of less than three months before signing the informed consent. * patients with cognitive impairment preventing them from understanding what is written in the patient information sheet or the informed consent, or from per-forming the self-administered questionnaires. * patients who started anticoagulant therapy for non-valvular atrial fibrillation with a direct oral anticoagulant .
acupuncture for post-thoracotomy pain

Conditions: Lung Cancer; Pain

Summary: pain after surgery for lung cancer (thoracotomy) may persist for years and require long-term analgesic use. prior studies have shown that acupuncture reduces pain and medication use in the early post-operative period after abdominal surgery, suggesting that acupuncture may have a role in preventing chronic post-thoracotomy pain. this study is being done in order to determine the effects of acupuncture on pain in patients undergoing surgery for lung cancer.

rationale: acupuncture is the insertion of very fine needles into the skin to treat symptoms. in recent years, researchers have come to understand how acupuncture might work in terms of nerve stimulation and the release of chemical messages in the body. researchers have found evidence that acupuncture is useful in treating a variety of conditions, including headache, nausea, and pain after surgery. pain is a common problem after surgery for lung cancer. many patients experience pain in the first few days after surgery, despite medication. in some patients, this pain can last for many months or years afterwards. purpose: a pilot study of acupuncture in patients undergoing lung cancer surgery was conducted previously and found that this study was feasible to implement and well-received by patients. we now wish to conduct a larger study in order to determine the effects of acupuncture on pain in patients undergoing surgery for lung cancer. * to determine whether acupuncture versus placebo acupuncture after thoracotomy reduces pain or analgesic use * to determine whether acupuncture affects the immediate post-operative period and/or 30, 60,90 days and approximately 12 months later.

Eligibility criteria:
inclusion criteria: * patients undergoing unilateral thoracotomy at memorial sloan-kettering cancer center (mskcc) * age greater than or equal to 18 years old. exclusion criteria: * any of the following procedures: hemiclamshell, clamshell, extrapleural approach, chest wall involvement, esophagectomy. these more extensive procedures have a higher risk of complications. * acupuncture treatment in the previous six weeks, to discount any persisting effect of acupuncture * platelets \ 2.5 or absolute neutrophil count (anc) \< 0.5; though it would be unusual for any patient to be operated on with such values, it seems wise as a precautionary measure to avoid risk of bleeding from acupuncture. * known cardiac conditions constituting a high or moderate risk of endocarditis as defined by the american heart association criteria * patients unable to remove studs without assistance, who have no home assistance, and who are unable or unwilling to return to the hospital in the event that they decide to remove studs before the post-discharge visit.

Keywords: acupuncture pain lung cancer thoracotomy surgery
bcd to measure the ed95 of remimazolam-assisted sedation in arteriovenous fistula creation surgery

Conditions: Uremia

Summary: this study intends to measure the ed95 of remimazolam-assisted sedation in arteriovenous fistula creation by bcd.

operative venous fistula (avf) under local anaesthesia is a common surgical procedure for long-term haemodialysis patients. a common surgical procedure for patients with renal failure on dialysis. however, due to the long duration of the procedure, patients are prone to anxiety and nervousness that especially if it is difficult to keep quiet during the operation, it may lead to blood pressure fluctuation and other complications, affecting the operation's smooth progress of the procedure. moderate sedation is particularly important in this type of surgery, as it can effectively relieve the patient's tension and stabilise vital signs, it can effectively relieve the patient's tension, stabilise vital signs and reduce the patient's discomfort, thus contributing to the successful completion of the operation.this study intends to measure the ed95 of remazolam-assisted sedation in arteriovenous fistula creation by bcd. this will provide a scientific basis for anaesthetic drug selection in uremic patients.

Eligibility criteria:
inclusion criteria: * 18-65 years old (including borderline values). * elective surgical patients under local anaesthesia for operation of avf * voluntary participation in this study and signing of informed consent. * american society of anesthesiologists (asa) classification \< grade iv. * bmi range: 18-28kg/m2 (including borderline values). exclusion criteria: * hypersensitivity to remimazolam or benzodiazepines. * patients with severe cardiac, pulmonary, neurological diseases or liver failure. -- preoperative use of sedative drugs, anticonvulsants, etc. * patients who cannot cooperate with postoperative recovery or follow-up. * vulnerable groups, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, illiterates, etc.

Keywords: biased coin design uremia remimazolam ed95
clinical study of the effectiveness, tolerability and safety of the drug "anti-spike, gel, 100 g in bottles in package no. 1" produced by the republican unitary enterprise "unitekhprom bsu", with a single intraperitoneal use after surgery in adult patients with acute phlegmonous appendicitis

Conditions: Abdominal Adhesions

Summary: the purpose of the clinical trials is the evaluation of the effectiveness and safety of a single intraperitoneal use of the drug "antispike, gel, 100 g in a bottle" produced by unitary enterprise unitehprom bsu, belarus in patients after surgical control of acute phlegmonous appendicitis to prevent abdominal adhesions.

the prospective, randomized, placebo-controlled, single-blind clinical trial of the effectiveness, tolerability and safety of the drug "antispike, gel, 100 g in a bottle" produced by unitary enterprise unitehprom bgu, republic of belarus, in adult patients after surgery for acute phlegmonous appendicitis. research objectives: * to evaluate the immediate, rapid and long-term results of using antispike as a drug for preventive adhesions in patients who have a medium and high risk factor for the development of adhesions and are undergoing surgery for acute phlegmonous appendicitis; * identify the possibility of undesirable effects that may occur when using the drug; * to conduct a comparative assessment of the immediate results of using the drug antispike as a means of preventing adhesions in patients with minor phlegmonous appendicitis with an effect in the control group, in patients in whom anti-adhesion drugs were not used; * detailed description of the conditions and method of use of the antispike drug.

Eligibility criteria:
inclusion criteria: * presence of acute phlegmonous appendicitis requiring surgical intervention. * presence of medium or high risk factor for the development of adhesions of the abdominal cavity; * age of patients from 18 to 65 years. * absence of severe concomitant diseases in decompensation stage, oncologic diseases, as well as diseases requiring steroid therapy. * presence of written informed consent of the patient to participate in the study. * the patient's ability to fulfill the instructions of the research physician and comply with the study design. exclusion criteria: * at the subject own request without explaining the reasons for the behavior. * at the request of the physician-researcher if the subject violates the requirements of the protocol in terms of diet, smoking, consumption of alcoholic beverages, and use of medications without the prescription of the physician-researcher. * for reasons independent of the subject and the research physician, if the subject has drug intolerance or other life-threatening or life-threatening adverse reactions to drug administration that require emergency pharmacotherapy.

Keywords: phlegmonous appendicitis ketorolac tromethamine gel abdominal adhesions
the effect of head tilt and soft surface on virtual svv in normal subjects

Conditions: Vestibular Nerve Diseases

Summary: the sense of gravity is one of the important input of our balance system. the utricle is the key structure on this subject but the contribution of the proprioceptive receptors is also important. the aim of this study is to measure the effect of different angles of head tilt and soft surface on svv in healthy subjects with a new automated system.

two different settings will be used. in the first experiment, healthy subjects will make 15, 30, and 45-degree head tilt to the left and right side while they are standing. in every position, 3 measurements will be done. in the second experiment, 40 health subjects will make the same head maneuvers on the 20 cm thick soft surface. we will compare the effects of both head tilt and soft surface. all measurements will be done with a virtual svv system(interacoustics).

Eligibility criteria:
inclusion criteria: * no ear disease * no neurologic disease * no surgery for ear, brain or musculoskeletal system exclusion criteria: * diabetes mellitus * drug use effective on central nervous system
characteristics, adherence, and persistence among multiple sclerosis patients treated with disease-modifying therapies

Conditions: Multiple Sclerosis

Summary: this retrospective, observational cohort study used administrative claims data contained in the international business machines (ibm)® truven marketscan® research databases to describe demographic, clinical, and treatment characteristics in patients with multiple sclerosis (ms) who were initiated on siponimod, and other food and drug administration (fda)-approved disease-modifying therapies (dmts). the study time period was from march 2018 through june 2020 (most recent available data) and included a 1-year baseline period and a variable-length follow-up period (a minimum of 6 months follow-up required for post-index outcomes). the index date was defined as the date of the first claim for siponimod or other ms-specific treatment on or after march 2019. the data analysis was performed on a combination of early view and standard view data. the initial data analysis was from standard marketscan data used for patients with index data prior to the year 2019. both standard view and early view data were used for patients indexed after january 1, 2019. the early view data provided additional visibility as it contains an additional 2 quarters of data compared to standard data.


Eligibility criteria:
inclusion criteria * with 1 or more claims of siponimod or ms-related fda-approved dmt during the index calendar year. the date of first claim was the index date. * with 1 or more ms diagnosis for 12 months prior to the index date \[inclusive\]. * were continuously enrolled in pharmacy and medical benefits for 12 months prior to the index date \[inclusive\]. * include patients who were 18 years or older on the index date. * include patients continuously enrolled in pharmacy and medical benefits from the index date \[inclusive\] to 6 months/12 months post-index date. exclusion criteria • patients with 1 or more claims of index drug within 12 months prior to index date.
acupuncture for migraine: a functional magnetic resonance imaging (fmri) study

Conditions: Migraine

Summary: selecting acupoints along meridians is the predominant principle in acupuncture treatment, and it is also considered to ensure acupuncture efficacy. this experiment is to investigate whether specific brain networks gradually come in formation in accordance with this kind of acupoint selection methods.

every participants in the four intervention groups will go through functional magnetic imaging (fmri) scan four times: the 1st scan will be performed at their baselines; the 2nd scan will be done after 2 courses (10 times) acupuncture treatment; the 3rd scan will be performed when the 4 courses end; the 4th scan will be operated after three-month enrollment. volunteers in waiting list group will undergo the above scans at the same time points in exception of acupuncture treatment.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of non-aura migraine formulated by the international headache society in 2004 exclusion criteria: * people with other types of headache * people with organic cerebral disorders * people with primary disorders * people in moderate or severe anxiety or depression * people in pregnancy

Keywords: acupuncture migraine specific acupoints brain network
a multi-center trial of botox for severe urge urinary incontinence

Conditions: Urinary Incontinence

Summary: the purpose of the study is to determine how effective botox is in reducing the amount of urine leaked and which dose of botox is more effective and safe in those who have urinary urge incontinence.

a multi-center clinical trial of botulinum-a toxin (botox) for refractory urge incontinence.

Eligibility criteria:
inclusion criteria: * female subjects 21-90 years of age * subjects has urinary incontinence on 3 day bladder diary * subject has severe incontinence * urine dipstick or urine culture negative for urinary tract infection * cystometrogram without stress urinary leakage * must have failed at least one anti-cholinergic medication * negative urine pregnancy test on day of administration of study medication exclusion criteria: * history of carcinoma of the bladder * presence of foreign body in the bladder, cystitis or other correctable etiology for urge urinary incontinance * gross fecal incontinence * known allergy to sulfa or ciprofloxacin or to lidocaine * any medical condition that may put the subject at increased risk with exposure to botox * females who are pregnant, breast-feeding, or planning a pregnancy during the study or who are of child-bearing potential * known allergy to any of the components in the study medication * prior documented resistance to botox * evidence of recent alcohol or drug abuse * concurrent participation in another investigational drug or device study within 30 days
helicobacter pylori eradication and follow-up

Conditions: Helicobacter Pylori Infection

Summary: this randomized controlled clinical trial will estimate the eradication efficacy of different therapy for helicobacter pylori treatment. the completion of this trial will expand new therapy for the treatment of helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.


Eligibility criteria:
inclusion criteria: * participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (icf). * 18-75 years old on the day of signing the icf. * helicobacter pylori infection confirmed by 13c-urea breath test or rapid urease test. exclusion criteria: * patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases. * subjects or guardians refused to participate in the trial. * alcohol and/or drugs abuse (addiction or dependence) or poor compliance with doctor's judgment. * have taken antibiotics, bismuth, proton pump inhibitors or chinese traditional medicine 4 weeks before treatment. * pregnant or lactating women. * active peptic ulcer. * allergic to drugs used in the trial. * any other circumstances that are not suitable for recruitment.
overcoming psychiatric barriers to the treatment of hepatitis c

Conditions: Hepatitis C; Substance Use Disorders; Mental Disorder

Summary: the purpose of this study is to develop and evaluate a 9-month psychosocial intervention that will assist patients with hepatitis c in overcoming barriers that prevent them from becoming appropriate candidates for interferon therapy.

the purpose of this study is to develop and evaluate a 9-month psychosocial intervention that will assist patients with hepatitis c in overcoming barriers that prevent them from becoming appropriate candidates for interferon therapy. patients who have been deferred from therapy due to mental health or substance abuse issues will work with the team psychologist on following through with the hepatologist's treatment recommendations that would lead to becoming eligible for interferon therapy.

Eligibility criteria:
inclusion criteria: * patient has confirmed diagnosis of hcv; * patient has expressed an interest in undergoing interferon treatment; * patient is deferred from interferon therapy for psychiatric, alcohol use, or other psychosocial issues; * patient must be completely medically cleared by the hepatologist with no outstanding medical conditions that would deem them ineligible from treatment; * patient must have only psychiatric issues and/or substance use issues; but otherwise no other contraindications for treatment. exclusion criteria: * patient has a diagnosis of schizophrenia, psychosis; * patient resides in a psychiatric residential facility; * patient attempted suicide in the past five years; * patient is a current intravenous drug user; * patient is cognitively or decisionally-impaired due to brain disease or injury; * patient has advanced liver disease that precludes them from interferon treatment; * patient has other medical comorbidities that may exclude them from interferon treatment; * patient does not want to pursue interferon treatment at the present time; * patient has significant financial constraints, such as no insurance or homelessness, that would prevent them acquiring mental health or substance abuse services; * no access to telephone service; * non-english speaking.

Keywords: hepatitis c mental disorder substance use psychosocial intervention